We reviewed the evidence on medicines for type 2 diabetes, and made and updated recommendations for people with no relevant comorbidities and for people with common comorbidities. We also made changes to recommendations on insulin, in the context of the withdrawal of insulin products and known brand shortages. For more details, see update information.
As always, these guidelines are for the NHS rather than people with T2 diabetes, and are therefore 95% about pharmaceutical prescribing.